U.S. Heparin Market Forecasts 2026 | Statistics Report

U.S. Heparin Market Size By Product (Low Molecular Weight Heparin, Unfractionated Heparin), By Application (Venous Thromboembolism, Atrial Fibrillation/Flutter, Coronary Artery Disease), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 – 2026

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology

1.1&nbsp;&nbsp;&nbsp; Market definitions

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; working

1.3&nbsp;&nbsp;&nbsp; Forecast calculations

1.4&nbsp;&nbsp;&nbsp; Data validation

1.5&nbsp;&nbsp;&nbsp; Data sources

1.5.1&nbsp;&nbsp;&nbsp; Secondary

1.5.1.1&nbsp;&nbsp;&nbsp; Paid sources

1.5.1.2&nbsp;&nbsp;&nbsp; Unpaid sources

1.5.2&nbsp;&nbsp;&nbsp; Primary

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; U.S. heparin industry 360&deg; synopsis, 2015-2026

2.1.1&nbsp;&nbsp;&nbsp; Business trends

Chapter 3&nbsp;&nbsp;&nbsp;US Heparin Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry segmentation

3.2&nbsp;&nbsp;&nbsp; Industry landscape, 2015 - 2026

3.3&nbsp;&nbsp;&nbsp; Industry impact forces

3.3.1&nbsp;&nbsp;&nbsp; Growth drivers

3.3.1.1&nbsp;&nbsp;&nbsp; Growing prevalence of chronic diseases

3.3.1.2&nbsp;&nbsp;&nbsp; High demand for anti-coagulant products

3.3.1.3&nbsp;&nbsp;&nbsp; Rising geriatric population in U.S.

3.3.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.3.2.1&nbsp;&nbsp;&nbsp; High risk of side effects

3.3.2.2&nbsp;&nbsp;&nbsp; High dependency on porcine

3.4&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4.1&nbsp;&nbsp;&nbsp; By product

3.4.2&nbsp;&nbsp;&nbsp; By application

3.4.3&nbsp;&nbsp;&nbsp; By distribution channel

3.5&nbsp;&nbsp;&nbsp; COVID-19 impact analysis

3.6&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.7&nbsp;&nbsp;&nbsp; Competitive landscape, 2019

3.7.1&nbsp;&nbsp;&nbsp; Company share analysis, 2019

3.7.2&nbsp;&nbsp;&nbsp; Company matrix analysis

3.8&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;US Heparin Market, By Product

4.1&nbsp;&nbsp;&nbsp; Key segment trends

4.2&nbsp;&nbsp;&nbsp; Low molecular weight heparin

4.2.1&nbsp;&nbsp;&nbsp; Market size, 2015 - 2026 (USD Million)

4.3&nbsp;&nbsp;&nbsp; Unfractionated heparin

4.3.1&nbsp;&nbsp;&nbsp; Market size, 2015 - 2026 (USD Million)

Chapter 5&nbsp;&nbsp;&nbsp;US Heparin Market, By Application 

5.1&nbsp;&nbsp;&nbsp; Key segment trends

5.2&nbsp;&nbsp;&nbsp; Venous thromboembolism

5.2.1&nbsp;&nbsp;&nbsp; Market size, 2015 - 2026 (USD Million)

5.3&nbsp;&nbsp;&nbsp; Atrial fibrillation/flutter

5.3.1&nbsp;&nbsp;&nbsp; Market size, 2015 - 2026 (USD Million)

5.4&nbsp;&nbsp;&nbsp; Coronary artery disease

5.4.1&nbsp;&nbsp;&nbsp; Market size, 2015 - 2026 (USD Million)

5.5&nbsp;&nbsp;&nbsp; Others

5.5.1&nbsp;&nbsp;&nbsp; Market size, 2015 - 2026 (USD Million)

Chapter 6&nbsp;&nbsp;&nbsp;US Heparin Market, By Distribution Channel 

6.1&nbsp;&nbsp;&nbsp; Key segment trends

6.2&nbsp;&nbsp;&nbsp; Hospital pharmacy

6.2.1&nbsp;&nbsp;&nbsp; Market size, 2015 - 2026 (USD Million)

6.3&nbsp;&nbsp;&nbsp; Retail pharmacy

6.3.1&nbsp;&nbsp;&nbsp; Market size, 2015 - 2026 (USD Million)

6.4&nbsp;&nbsp;&nbsp; Online pharmacy

6.4.1&nbsp;&nbsp;&nbsp; Market size, 2015 - 2026 (USD Million)

Chapter 7&nbsp;&nbsp;&nbsp;Company Profiles

7.1&nbsp;&nbsp;&nbsp; Competitive dashboard, 2019

7.2&nbsp;&nbsp;&nbsp; Amphastar Pharmaceutical

7.2.1&nbsp;&nbsp;&nbsp; Business overview

7.2.2&nbsp;&nbsp;&nbsp; Financial data

7.2.3&nbsp;&nbsp;&nbsp; Product landscape

7.2.4&nbsp;&nbsp;&nbsp; Strategic outlook

7.2.5&nbsp;&nbsp;&nbsp; SWOT analysis

7.3&nbsp;&nbsp;&nbsp; Changzhou Qianhong Biopharma Co , Ltd

7.3.1&nbsp;&nbsp;&nbsp; Business overview

7.3.2&nbsp;&nbsp;&nbsp; Financial data

7.3.3&nbsp;&nbsp;&nbsp; Product landscape

7.3.4&nbsp;&nbsp;&nbsp; Strategic outlook

7.3.5&nbsp;&nbsp;&nbsp; SWOT analysis

7.4&nbsp;&nbsp;&nbsp; Fresenius Kabi

7.4.1&nbsp;&nbsp;&nbsp; Business overview

7.4.2&nbsp;&nbsp;&nbsp; Financial data

7.4.3&nbsp;&nbsp;&nbsp; Product landscape

7.4.4&nbsp;&nbsp;&nbsp; Strategic outlook

7.4.5&nbsp;&nbsp;&nbsp; SWOT analysis

7.5&nbsp;&nbsp;&nbsp; Leo Pharma A/S

7.5.1&nbsp;&nbsp;&nbsp; Business overview

7.5.2&nbsp;&nbsp;&nbsp; Financial data

7.5.3&nbsp;&nbsp;&nbsp; Product landscape

7.5.4&nbsp;&nbsp;&nbsp; Strategic outlook

7.5.5&nbsp;&nbsp;&nbsp; SWOT analysis

7.6&nbsp;&nbsp;&nbsp; Nanjing King-Friend Biochemical Pharmaceutical

7.6.1&nbsp;&nbsp;&nbsp; Business overview

7.6.2&nbsp;&nbsp;&nbsp; Financial data

7.6.3&nbsp;&nbsp;&nbsp; Product landscape

7.6.4&nbsp;&nbsp;&nbsp; Strategic outlook

7.6.5&nbsp;&nbsp;&nbsp; SWOT analysis

7.7&nbsp;&nbsp;&nbsp; Pfizer, Inc

7.7.1&nbsp;&nbsp;&nbsp; Business overview

7.7.2&nbsp;&nbsp;&nbsp; Financial data

7.7.3&nbsp;&nbsp;&nbsp; Product landscape

7.7.4&nbsp;&nbsp;&nbsp; Strategic outlook

7.7.5&nbsp;&nbsp;&nbsp; SWOT analysis

7.8&nbsp;&nbsp;&nbsp; Sanofi

7.8.1&nbsp;&nbsp;&nbsp; Business overview

7.8.2&nbsp;&nbsp;&nbsp; Financial data

7.8.3&nbsp;&nbsp;&nbsp; Product landscape

7.8.4&nbsp;&nbsp;&nbsp; Strategic outlook

7.8.5&nbsp;&nbsp;&nbsp; SWOT analysis

7.9&nbsp;&nbsp;&nbsp; Shenzhen Hepalink

7.9.1&nbsp;&nbsp;&nbsp; Business overview

7.9.2&nbsp;&nbsp;&nbsp; Financial data

7.9.3&nbsp;&nbsp;&nbsp; Product landscape

7.9.4&nbsp;&nbsp;&nbsp; Strategic outlook

7.9.5&nbsp;&nbsp;&nbsp; SWOT analysis

7.10&nbsp;&nbsp;&nbsp; Yantai Dongcheng Biochemical Co , Ltd

7.10.1&nbsp;&nbsp;&nbsp; Business overview

7.10.2&nbsp;&nbsp;&nbsp; Financial data

7.10.3&nbsp;&nbsp;&nbsp; Product landscape

7.10.4&nbsp;&nbsp;&nbsp; Strategic outlook

7.10.5&nbsp;&nbsp;&nbsp; SWOT analysis

&nbsp;

U.S. Heparin Market

Inquiry Before Buying